Danaher (NYSE:DHR) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Danaher (NYSE:DHR) posted its quarterly earnings data on Monday. The conglomerate reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12, FiscalAI reports. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $6 billion.

Danaher Stock Up 0.5%

DHR stock opened at $195.79 on Tuesday. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35. Danaher has a twelve month low of $180.03 and a twelve month high of $242.80. The company’s 50 day moving average is $198.39 and its two-hundred day moving average is $214.70. The stock has a market cap of $138.56 billion, a P/E ratio of 38.85, a PEG ratio of 2.64 and a beta of 0.95.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 dividend on an annualized basis and a yield of 0.8%. Danaher’s dividend payout ratio is 31.75%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on DHR shares. Argus set a $265.00 price objective on shares of Danaher in a research note on Wednesday, January 14th. Guggenheim raised their price objective on shares of Danaher from $250.00 to $275.00 and gave the company a “buy” rating in a report on Friday, January 2nd. Leerink Partners raised their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “outperform” rating in a report on Friday, January 16th. Evercore decreased their price target on Danaher from $254.00 to $225.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Finally, Barclays decreased their price target on Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Eighteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $246.50.

Insiders Place Their Bets

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.80% of the company’s stock.

Institutional Trading of Danaher

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC acquired a new stake in Danaher during the third quarter worth approximately $25,000. WFA of San Diego LLC acquired a new position in shares of Danaher in the 2nd quarter valued at $26,000. Transamerica Financial Advisors LLC increased its holdings in shares of Danaher by 216.3% in the 4th quarter. Transamerica Financial Advisors LLC now owns 155 shares of the conglomerate’s stock valued at $36,000 after acquiring an additional 106 shares during the period. Birchwood Financial Partners Inc. acquired a new position in shares of Danaher in the 4th quarter valued at $41,000. Finally, Quattro Advisors LLC acquired a new position in shares of Danaher in the 4th quarter valued at $52,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.